Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Fuud’s Board of Directors resolves on a rights issue of units of approximately SEK 78.1 million

STOCKHOLM, May 20, 2022 08.30 CEST The Board of Directors of FUUD AB (publ) ("Fuud" or the "Company") has today resolved to issue up to 42,431,117 units with preferential rights for the Company's existing shareholders of initially approximately SEK 78.1 million before issue costs (the "Rights Issue"). Each unit consists of eight (8) shares and one (1) warrant issued free of charge. The subscription price is SEK 1.84 per unit, corresponding to SEK 0.23 per new share. Prior to the Rights Issue, the Company has received subscription commitments and has entered into agreements on guarantee

Hamlet Pharma Q3 Interim Report  January – March 2022

Hamlet Pharma has reached important milestones during the third quarter of the fiscal year 2021-2022. We have successfully completed the dose-escalation part of the ongoing clinical study in bladder cancer and detected significantly stronger effects on the tumor in patients receiving increasing doses of Alpha1H.The tumors were strongly affected in patients treated with five times higher amounts of Alpha1H without an increase in side effects. These results are very encouraging for our continued development of the clinical program. We have intensified the collaboration with experienced

Lipidor updates on Phase III study of AKP02 in treatment of psoriasis – half of patients now recruited

STOCKHOLM, Sweden, 20 May 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment in June 2022. Topline results from the Phase III study are expected during the third quarter of 2022.On 26 January, Lipidor announced that the first psoriasis patients had been enrolled in the company's Phase III clinical trial of AKP02 cutaneous spray. The observer-blind and placebo-controlled Phase III study included

Fuud communicates renegotiated terms for the acquisitions of GI-Boxen and Foodbox

STOCKHOLM, May 20, 2022 08.30 CET FUUD AB (publ) ("Fuud" or "the Company") announced on March 28, 2022 that the Company has entered into a conditional agreement to acquire 100 percent of the shares in GI-Boxen Sweden AB ("GI-Boxen") and Foodbox Scandinavia AB ("Foodbox”). The company and the sellers of GI-Boxen and Foodbox have today entered into supplementary agreements to the original agreements according to which the purchase price for the acquisitions is changed. Through the supplementary agreements, the parties have agreed that the total initial purchase price of SEK 55 million shall

Crown Energy AB Postpones First Quarter Report 2022

PRESS RELEASE 20/05/2022     Crown Energy AB (publ) will postpone the First Quarter Report for 2022, a new date for the publication of the report will be not later than 31 May 2022. Previously the publication of the Year-End report was scheduled for 20 May 2022.     More information     Yoav Ben-Eli, CEO Crown Energy AB +46 76 312 9793     ABOUT CROWN ENERGY Crown Energy is an international group providing customised solutions for housing, offices and associated services, as well as oil and gas exploration in Africa and the Middle East. For more

Interim report January – March 2022

The period in summary First quarter January 1 – March 31, 2022 –      On March 23 the first batch of Strangvac was released for sale in Sweden. –      Intervacc has applied for supplementary protection certificates (SPCs) for Strangvac in key European markets. SPCs are an intellectual property right that serves as an extension to a patent right. –      EMA extended the shelf life of the antigens used in Strangvac to 28 months. –      During February an application for a Permit for Sale and Distribution of Strangvac in the U.S. was submitted to the U.S. Department of

Interim Report January - March 2022

January 1st – March 31st 2022 · Net sales amounted to EUR 6 136 thousand (5 691) · EBITDA of EUR 64 thousand (49) and EBITDA margin of 1.0 % (0.9) · EBIT of negative EUR 38 thousand (48) and EBIT margin of -0.6% (-0.8) · Net earnings after tax of negative EUR 276 thousand (-339)   January ­– March key developments   · low IoT sales at the beginning of the year due to delays in expected projects in Sweden · Seasonal factors and global cost effects caused lower earnings in the first quarter · ZT Group signed the SPA to buy Talkpool Pakistan for a total of USD

Eurocine Vaccines publishes interim report for July 2021 – March 2022

Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby publishes the interim report for July 2021 to December 2022. Below is a summary of the report. The full report is available on the Eurocine Vaccines website and as an attachment.   2022-01-01 – 2022-03-31 (third quarter) · Results after tax for the quarter amounted to -5,6 Mkr (-4,6 Mkr) · Revenues for the quarter amounted to 0 Tkr (75 Tkr) · Earnings per share for the quarter amounted to -0,397 kr (-0,582 kr)   2021-07-01 – 2022-03-31 (nine month period) · Results after tax

Mangold Insight publishes its second analysis of Brighter

Brighter AB (publ) announces today that Mangold Insight has published its second analysis of Brighter. Link to the analysis (in Swedish)   For further information, please contact:Investor Relationsir@brighter.seCertified AdviserBrighter’s Certified Adviser är Mangold Fondkommission AB,+46 8 5277 5020, ca@mangold.se, www.mangold.se. About Brighter AB (publ)Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric

CS MEDICA A/S: Publication of half-year report for the financial year 2021/2022

CS MEDICA (”CS MEDICA” or the ”Company”) hereby publishes its half-year report for the period October 2021 – March 2022. The report is available as an attached document to this press release and on the Company's website (www.cs-medica.com). Below is a summary of the report.Performance highlights second quarter (January 2022 – March 2022) The circumstances following COVID19, and the current War in Ukraine have had and still has a great impact on our sales revenue, especially in the European Countries. Both incidents have negatively affected not only sales but also reduced the speed and

COLONY SIGNS 11,000 SQM GREEN LEASE AGREEMENT UNTIL 2030 WITH CGI

Colony acquired the Finnish headquarter of multinational consultancy firm CGI from NIAM in November 2021. A tenant dialogue was initiated within weeks, which has now resulted in a lease extension until 2030. In addition to the 11,000 sqm CGI lease, a number of new 500-1,000 sqm agreements are well progressed to further build atmosphere and footfall within the building."We are pleased that CGI remains as the anchor tenant in the building, showcasing the strength in Colony’s tenant offering of green hybrid office space in attractive locations in and around Helsinki. This gives further

Pharmacolog: Interim report January - March 2022

Press release: Uppsala, May 20, 2022. Pharmacolog i Uppsala AB’s (publ) interim report for the period January – March is now available on the company’s webbsite http://www.pharmacolog.com (Swedish only)Första kvartalet 1 januari – 31 mars 2022 · Koncernens nettoomsättning för perioden uppgick till 2 021 (2 464) KSEK. · Rörelseresultatet för koncernen för perioden uppgick till -4 318 (-2 379) KSEK. · Nettoresultat per aktie före och efter utspädning var för perioden -0,28 (-0,18) SEK. Väsentliga händelser under perioden januari - mars 2022       · B. Braun Spanien

Metso Outotec wins order for large iron ore pellet plant in Oman

Metso Outotec Corporation’s press release on May 20, 2022, at 09:00 a.m. EESTMetso Outotec has signed an agreement for the delivery of engineering and key equipment for an iron ore Grate Kiln pellet plant to Vulcan Pelletizing LLC. The plant is located in the industrial port of Sohar, the Sultanate of Oman. The value of the order is approximately EUR 33 million, and it has been booked in Metals’ Q2/2022 orders received. The pellet plant will supply pellets to Jindal Shadeed Iron & Steel LLC, Oman. Metso Outotec’s scope of delivery consists of the supply of core pelletizing plant

Trill Impact leads the 240 MSEK venture financing round in Cinclus Pharma

Trill Impact leads a 240 MSEK venture financing round in Cinclus Pharma AB, a Swedish late-stage biopharmaceutical company committed to improving the medical outcome for patients suffering from severe stomach acid-related disorders. Cinclus Pharma’s lead candidate, linaprazan glurate, is a P-CAB (potassium-competitive acid blocker) and represents a new class of anti-secretory medicines targeting patients unresponsive to existing treatment options.Linaprazan glurate holds the potential to decrease the unnecessary use of antibiotics, thereby reducing the development of antimicrobial

Genetic Analysis AS: Mandatory notification of trade – Primary Insider

OSLO, NORWAY - 20 May 2022: Genetic Analysis AS (“GA” or “the Company”) announce that a member of the management has bought GEAN-shares.Ronny Hermansen, CEO in Genetic Analysis AS, has through the fully owned company InVitroDia AS today bought 23.000 GEAN-shares at an average price of 3,68 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 192.040 shares and 49,998 tradable subscription rights GEAN T01/T02.

Record date for consolidation of shares (reverse split) in Bergs Timber AB (publ) set for 31 May 2022

PRESS RELEASE 20 May 2022     At Bergs Timber's Annual General Meeting, May 5, 2022, it was decided to consolidate the company's existing 346,728,283 shares (reverse split), whereby ten (10) shares are consolidated into one (1) share. The Board was authorised to decide on the record date for the consolidation.   The Board of Directors has decided to set the record date for the consolidation to 31 May 2022, which means that the last day for trading in the share before the consolidation is 27 May 2022. The first day for trading in consolidated shares is 30 May 2022.

Eurobattery Minerals publishes financial figures for Q1 2022 – Strongest quarter in company’s history ever

Stockholm, 20th of May 2022 – The mining company Eurobattery Minerals AB (Nordic Growth Market: “BAT ” and Börse Stuttgart: “EBM ”; in short: “EBM”, “Eurobattery” or “the Company”), published its figures for the first quarter of 2022 today. “We are proud and happy about the in every sense strongest quarter in our company’s history. Backed by our directed issue of convertibles, we received SEK 18 million right at the beginning of this

Hufvudstaden welcomes IGNITE Training hub to Bibliotekstan

This autumn, a completely new training concept will open on Norrlandsgatan 10 in Stockholm. IGNITE Training Hub will be a new premium facility specialising in high-intensity group exercise programmes. The approximately 800 sqm facility will be on street level in Hufvudstaden’s newly renovated property at the intersection of Norrlandsgatan and Smålandsgatan in central Stockholm.The IGNITE Training Hub concept has been founded by Per Althini, previous developer of Metropolis gym with three facilities located on Birger Jarlsgatan, in the The Royal tennis Hall and in Åre.   -          “We

Lehto Group Plc: Lehto and banks have agreed on financing as part of approximately EUR 50 million financing package

Lehto Group PlcInsider information20 May, 2022 at 8.30 a.m (EET)Lehto Group Plc (”Lehto”) announced on 28 April 2022 that it is preparing a financing package to implement its updated strategy. Lehto has signed a binding preliminary agreement on new financing (”Preliminary Agreement”) with OP Corporate Bank Plc (”OP”) and Nordea Bank Plc (“Nordea”). Preliminary Agreement defines the amounts, main conditions and principles of bank financing, and main terms of the convertible bond issuance. Preliminary agreement is part of approximately EUR 50 million financing arrangement under

Raisio and the Nordic Umami Company to partner

Press Release, May 20, 2022 Raisio and the Nordic Umami Company have agreed on a partnership to explore opportunities for upcycling Raisio’s plant-based side streams to develop natural umami. The partnership supports Raisio’s corporate responsibility program, as one of its’ aim is to minimize food and production waste and better utilize by-products.   The Nordic Umami Company develops sustainable flavor innovations from food industry by-products. The company focuses on umami, the ’meaty’ delicious flavor that is naturally missing from plant-based proteins. In a process based on

Nordhealth AS: Q1/2022 presentation

Please find attached the presentation of Nordhealth AS first quarter 2022 results. The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Mari Orttenvuori on the 20th of May 2022 at 08:00 am CET. Please use the following link: https://us02web.zoom.us/j/88659009481 The presentation will be recorded and made available on www.nordhealth.com For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Mari Orttenvuori, CFO mari.orttenvuori@nordhealth.com +358 46

Aquaporin announces Q1 2022 Trading Statement: Strong revenue momentum in all business segments – outlook maintained

Aquaporin A/S, Nymøllevej 78, DK-2800 Kongens Lyngby, aquaporin.com, VAT no.: DK28315694Company announcementNo. 06/2022 Copenhagen, Denmark, May 20, 2022 –Aquaporin A/S (AQP.CO) (“Aquaporin” or the “Company”), an innovative water technology company dedicated to natural water treatment, today announced the Company's Q1 2022 Trading Statement for the period January 1-March 31, 2022. Financial highlights as of March 31, 2022Comparative figures for 2021 are shown in brackets throughout the report. · Revenue amounted to DKK 7.1 million in Q1 2022, growing 223% year-on-year (vs.

BEWI – Results for the first quarter of 2022

BEWI, a leading provider of packaging, components, and insulation solutions, today reported its results for the first quarter of 2022. BEWI recorded net sales of 230.2 million euro for the first quarter of 2022, up by 55 per cent compared to the 148.9 million euro for the same quarter last year. The company recorded 37 per cent organic growth, mainly from higher sales prices. Adjusted EBITDA came in at 34.4 million, which is the company’s highest ever recorded result and a doubling of the EUR 16.7 million recorded for the first quarter of 2021. “We are very pleased to see our growth

Mandatory notification of trade

On May 19, 2022, Systemintegration ApS, controlled by Ib Kunøe acquired 132,496 shares in Atea ASA at a price of NOK 107,10. Ib Kunøe is primary insider and the Chairman of the Board of Atea ASA. Following the transaction, Ib Kunøe and close associates controls 31,749,606 shares in Atea ASA, representing 28.3% of the share capital. For further information, please contact:Robert Giori, CFO Atea ASA, mobile +47 934 09 188Ole Johan Fjellestad, Group Chief Accountant, mobile +47 992 74 829

There are no items matching the current filter
There are no more items matching the current filter
Back to top